By Hyunjin Choi
JLK Inspection, an AI-enhanced medical solution provider, announced that it will seek Initial Public Offering(IPO) to go public on KOSDAQ, submitting the registration statement to the Financial Services Commission after passing the preliminary screening review by Korean Exchange(KRX) on the 30th last month.
The market is eyeing on JLK Inspection in the process of IPO under the technology exception policy since it will be the first AI-based medical company on the KOSDAQ market. The company plans to secure approximately a maximum of KRW 29 bn (USD 25 mm) by offering 2 million stocks with the IPO price band between 11,000 won and 14,500 won per share.
The IPO price is to set up during the book-building session on Nov. 26-27. Public subscriptions will be held on Dec. 2-3, and JLK Inspection expects that the listing is finalized within this year. The lead manager is Korea Investment & Securities Co.
Founded in 2014, JLK Inspection(a Born2Global member from 2017~2019) is a medical solutions provider specializing AI-enhanced technology.
The company released AIHuB, an all-in-one medical platform to detect 37 medical conditions in 14 different body parts: strokes, Alzheimer’s, prostate cancer, lung cancer, thyroids cancer, breast cancer, and joint disease. To support a doctor’s diagnosis, AIHuB analyzes nationwide scales of MR images up to 1.5M slides from 14K people based on deep learning technology. After the analysis, it provides a real-time diagnosis support on site for practitioners.
While competitors use only CT to detect diseases, AIHuB heightens the accuracy, using CT, MRI, MRA, and mammography data all together.These solutions are approved by the Ministry of Food and Drug Safety in South Korea as an AI-based class Ⅲ computer aided diagnosis system. It has obtained CE mark for AI-based medical solutions in accordance with the European Medical Device Directive(MDD).
By Hyunjin Choi
JLK Inspection Targeting Overseas Market with European CE Certifications for the AI-enhanced Medical Image Analytics Solutions. JLK Inspection, an AI-based medical analysis company(CEO Wontae Kim, Dongmin Kim), has geared up to enter the overseas market, firstly targeting the European market.
The company announced that it has obtained the CE quality certifications it needs to export its products, AI-based medical image analysis solutions.The solutions that have achieved CE certifications are as follows: JAD-02K(Brain parcellation & Cortical thickness analysis solution), JBA-01K(Brain MR image analysis solution), JBS-04K(Brain CT image analysis solution), JLK-01K(Lung CT image analysis solution), JLK-02K(Lung X-ray analysis solution)
JAD-02K analyzes MR images of the brain on the 3-dimensional basis and compares the result with norm figures of the same age groups. JBA-01K provides information on cerebral aneurysm while JBS-04K supplies data on cerebral hemorrhage to the practitioners. JLD-01K garners the figurative data on the diameter and volume of lung areas, and JLD-02K transforms pattern information of lung X-ray into figures by analyzing lung X-ray images.
These CE certifications on the five solutions were preceded by two European CE certifications, brain MR image analytics solution (JBS-01K) and prostate MR image analytics solution(JPC-01K) in May this year.
“This is a meaningful result that the solutions from JLK Inspection meet the international requirements for functions and qualifications in terms of effectiveness and stability. We will strive to prove our solutions’ competitiveness through successful global market entry,” said Dongmin Kim, CEO of JLK Inspection.